Healthy Adult Female Participants
4
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 2 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
ServierVorasidenib
ShionogiEnsitrelvir
Clinical Trials (2)
Total enrollment: 52 patients across 2 trials
A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants
Start: Nov 2025Est. completion: Mar 202628 patients
Phase 1Completed
A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants
Start: Dec 2024Est. completion: Apr 202524 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.